sulfasalazine has been researched along with Acute Disease in 84 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| " At the time of a planned interim toxicity analysis, more patients with grade ≥3 diarrhea received sulfasalazine than received placebo (29% vs 11%, P=." | 9.22 | N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. ( Bearden, JD; Iott, MJ; Liem, B; Liu, H; Loprinzi, CL; Martenson, JA; Miller, RC; Mowat, RB; Petereit, DG; Sapiente, R; Seeger, GR; Sloan, JA, 2016) |
| "To evaluate the efficacy of sulfasalazine (SSZ) in the prevention of recurrent flares of acute anterior uveitis (AAU)." | 9.10 | Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. ( Bonilla, G; Fernández-Melón, J; Fonseca, A; Gijón-Baños, J; Hidalgo, V; Martín-Mola, E; Muñoz-Fernández, S; Ruiz-Sancho, D; Schlincker, A, 2003) |
| "A double-blind therapeutic trial of azathioprine in 20 patients with acute proctocolitis was performed over a 3-month period." | 9.04 | Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. ( Babbini, M; Caprilli, R; Carratù, R, 1975) |
| " The present study examined intestinal anti-inflammatory activity of coumarin and its derivative, the 4-hydroxycoumarin on experimental ulcerative colitis in rats." | 7.74 | Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. ( Cestari, SH; Di Stasi, LC; Luchini, AC; Pellizzon, CH; Rodrigues-Orsi, P; Seito, LN; Witaicenis, A, 2008) |
| " In patients with inflammatory bowel diseases, the use of 5-aminosalicylic acid or sulfasalazine was not associated with increased risk of acute pancreatitis." | 7.72 | Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. ( Floyd, A; Munk, EM; Nørgård, B; Pedersen, L; Rasmussen, HH; Sørensen, HT, 2004) |
| " At the time of a planned interim toxicity analysis, more patients with grade ≥3 diarrhea received sulfasalazine than received placebo (29% vs 11%, P=." | 5.22 | N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. ( Bearden, JD; Iott, MJ; Liem, B; Liu, H; Loprinzi, CL; Martenson, JA; Miller, RC; Mowat, RB; Petereit, DG; Sapiente, R; Seeger, GR; Sloan, JA, 2016) |
| "To evaluate the efficacy of sulfasalazine (SSZ) in the prevention of recurrent flares of acute anterior uveitis (AAU)." | 5.10 | Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. ( Bonilla, G; Fernández-Melón, J; Fonseca, A; Gijón-Baños, J; Hidalgo, V; Martín-Mola, E; Muñoz-Fernández, S; Ruiz-Sancho, D; Schlincker, A, 2003) |
| "A double-blind therapeutic trial of azathioprine in 20 patients with acute proctocolitis was performed over a 3-month period." | 5.04 | Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. ( Babbini, M; Caprilli, R; Carratù, R, 1975) |
| "Sulfasalazine, consisting of 5-aminosalicylic acid bound to sulfapyridine by a diazo bond, was first used for treatment of ulcerative colitis in the early 1940s and later found effective in placebo-controlled trials for acute disease and for long-term maintenance of remission." | 4.81 | Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. ( Schroeder, KW, 2002) |
| "Although this isolated case of sulfasalazine- related interstitial nephritis cannot lead to definite conclusions, treatment with corticosteroids was effective in this patient and should be considered irrespective of the time of exposure to sulfasalazine." | 3.76 | Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids. ( Alivanis, P; Aperis, G; Arvanitis, A; Karvouniaris, N; Lambrianou, F; Paliouras, C; Zervos, A, 2010) |
| " The present study examined intestinal anti-inflammatory activity of coumarin and its derivative, the 4-hydroxycoumarin on experimental ulcerative colitis in rats." | 3.74 | Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. ( Cestari, SH; Di Stasi, LC; Luchini, AC; Pellizzon, CH; Rodrigues-Orsi, P; Seito, LN; Witaicenis, A, 2008) |
| " In patients with inflammatory bowel diseases, the use of 5-aminosalicylic acid or sulfasalazine was not associated with increased risk of acute pancreatitis." | 3.72 | Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. ( Floyd, A; Munk, EM; Nørgård, B; Pedersen, L; Rasmussen, HH; Sørensen, HT, 2004) |
| "We report a case of seizures with acute encephalopathy in a female patient under sulfasalazine treatment for polyarthritis." | 3.71 | [Sulfasalazine neurotoxicity]. ( Chadenat, ML; Dechy, H; Dorra, M; Dupont, C; Morelon, S; Raffin-Sanson, ML; Rouveix, E, 2001) |
| "43 patients with an acute relapse of ulcerative colitis proven by the pertinent endoscopic-macroscopic and histologic criteria were randomized to receive a 6-week course of either 1 g SASP (n = 21) or the equivalent dose of 0." | 2.66 | Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. ( Fleig, WE; Laudage, G; Riemann, J; Sommer, H; Stange, EF; Wellmann, W, 1988) |
| "Forty five patients with acute ulcerative colitis were randomly allocated to receive (a) sulphasalazine, (b) levamisole, or (c) a combination of sulphasalazine and levamisole." | 2.65 | Controlled therapeutic trial of levamisole and sulphasalazine in acute ulcerative colitis. ( Gajos, L; Hermanowicz, A; Nowak, A, 1984) |
| "Crohn's disease and ulcerative colitis, together popularly known as inflammatory bowel disease (IBD), are characterized by a number of extraintestinal manifestations." | 2.46 | Pancreatitis in inflammatory bowel diseases. ( Das, K; Pitchumoni, CS; Rubin, A, 2010) |
| "Radiation enteritis is a severe problem in patients receiving irradiation of the abdomen or pelvis in the course of cancer treatment." | 2.44 | Medical prevention and treatment of acute and chronic radiation induced enteritis--is there any proven therapy? a short review. ( Böcker, U; Singer, MV; Wenz, F; Zimmerer, T, 2008) |
| "The main standards of Crohn's disease therapy are presented on the bases of the small bowel Crohn's disease." | 2.41 | [Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002) |
| "Lymphocytic colitis is a rare clinicopathologic syndrome, characterized by chronic watery diarrhea, diffuse inflammatory changes in the colonic mucous in spite of normal findings on colonoscopy and marked intraepithelial lymphocytic infiltration on biopsy." | 2.41 | [Lymphocytic colitis: hypopotassemia as a complication and an association with toxic multinodular goiter]. ( Arenas Gracia, M; Calduch Broseta, JV; Martínez López, V; Mata Medina, B; Segarra Soria, MM; Serrano Corredor, MS, 2000) |
| "The role of salicylates in Crohn's disease is limited to the mild activity phase; further data are required to clarify its role in maintenance on remission." | 2.41 | New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. ( Campieri, M, 2002) |
| "We recently experienced a case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis." | 1.35 | [A case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis]. ( Choi, HS; Hahm, JS; Han, DS; Joo, YW; Lee, HL; Lee, OY; Son, CN; Yoon, BC, 2008) |
| "A kidney biopsy showed acute tubulointerstitial nephritis with an intense lymphocytic infiltrate and tubular necrosis." | 1.35 | A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. ( Augusto, JF; Chennebault, JM; Cousin, M; Croue, A; Sayegh, J; Simon, A; Subra, JF, 2009) |
| "Crohn's disease is a chronic idiopathic slowly developing transmural inflammation of the digestive system." | 1.34 | Sinonasal involvement as a rare extraintestinal manifestation of Crohn's disease. ( Bertrand, B; Daele, J; Dartevelle, M; Eloy, P; Fridman, V; Goffart, Y; Leruth, E; Melange, M; Nollevaux, MC, 2007) |
| " Medical treatment, including increased dosage of steroids, failed to control UC and acute thrombocytopenia in this patient." | 1.33 | Acute thrombocytopenia associated with preexisting ulcerative colitis successfully treated with colectomy. ( Hisada, T; Iida, T; Ishizuka, T; Kusano, M; Masuo, T; Miyamae, Y; Mizuide, M; Mori, M; Okada, S; Sagawa, T; Shibusawa, N, 2006) |
| "An acute respiratory failure occurred 36 hours after from admission due to an obstructive and desquamative necrosis of the tracheobronchial epithelium." | 1.31 | [Fatal toxic respiratory epitheliolysis. Subacute tracheo-bronchial desquamation in Stevens-Johnson syndrome]. ( Hazouard, E; Machet, L; Martin, L; Maurage, C; Michalak-Provost, S, 2001) |
| "Among 1613 patients treated for acute pancreatitis in 1993, drug induced acute pancreatitis was diagnosed in 22 patients (incidence 1." | 1.29 | Drug induced acute pancreatitis: incidence and severity. ( Dröge, M; Gottesleben, F; Lankisch, PG, 1995) |
| "Pancreatitis is generally regarded to be an extra-intestinal complication of Crohn's disease unless the duodenum is directly involved." | 1.29 | Crohn's disease associated with pancreatitis of unknown etiology: a case report. ( Arakawa, S; Omata, F; Takahashi, H; Ueno, F, 1993) |
| "We report a case of acute encephalopathy in a patient with Crohn's disease who had taken sulfasalazine for 1 month." | 1.29 | Sulfasalazine-associated encephalopathy in a patient with Crohn's disease. ( Achten, E; Dewilde, D; Mast, A; Pauwels, W; Schoonjans, R; Van Den Abeele, G; Van Maele, V, 1993) |
| " Upon recovery, sulfasalazine was reintroduced at lower dosage (2 Gm/day), and the patient repeated the clinical and biological picture of acute pancreatitis (serum amylase of 710 and lipase 1010 u." | 1.28 | [Acute pancreatitis caused by salazopyrine. An unusual association]. ( Delgado Fontaneda, E; García Campos, F; Ibarra Peña, B; Moretó Canela, M; Ruiz Rebollo, L, 1991) |
| "A 43-year-old female suffering from ulcerative colitis did not improve under therapy with sulfasalazine." | 1.27 | Acute ulcerative colitis--a rare complication of sulfasalazine therapy. ( Domschke, S; Ruppin, H, 1984) |
| " LST was negative before attempting desensitization and became positive when the dosage of SASP increased to 100 mg daily." | 1.27 | A case of salicylazosulfapyridine (Salazopyrin)-induced acute pancreatitis with positive lymphocyte stimulation test (LST). ( Arakawa, H; Chiba, M; Horie, Y; Ishida, H; Masamune, O, 1987) |
| "Ulcerative colitis (UC) and Crohn's disease (CD) can lead to perforation, abscesses and peritonitis." | 1.27 | [Acute manifestations in Crohn disease and ulcerative colitis. Conservative treatment of acute situations]. ( Goebell, H, 1988) |
| "Acute attacks of ulcerative colitis should be treated without delay and corticosteroids should be used systemically and topically." | 1.26 | Diagnosis and medical treatment of ulcerative colitis. ( Jewell, DP, 1982) |
| "Spontaneous adrenal hemorrhage is a rare condition that carries a high mortality." | 1.26 | Adrenal hemorrhage during the treatment of ulcerative colitis with adrenocorticotropic hormone. ( Simpson, WT, 1979) |
| "In acute exacerbations of ulcerative colitis, the potential difference was reversed, the luminal side being positive." | 1.25 | Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and ulcerative colitis. ( Edmonds, CJ, 1970) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (38.10) | 18.7374 |
| 1990's | 20 (23.81) | 18.2507 |
| 2000's | 23 (27.38) | 29.6817 |
| 2010's | 8 (9.52) | 24.3611 |
| 2020's | 1 (1.19) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, ZH | 1 |
| Zhang, HJ | 1 |
| Deng, AJ | 1 |
| Wang, B | 1 |
| Li, ZH | 1 |
| Liu, Y | 1 |
| Wu, LQ | 1 |
| Wang, WJ | 1 |
| Qin, HL | 1 |
| Shelat, VG | 1 |
| Bartal, C | 1 |
| Sagy, I | 1 |
| Barski, L | 1 |
| Zu Hoerste, MM | 1 |
| Walscheid, K | 1 |
| Tappeiner, C | 1 |
| Zurek-Imhoff, B | 1 |
| Heinz, C | 1 |
| Heiligenhaus, A | 1 |
| Miller, RC | 1 |
| Petereit, DG | 1 |
| Sloan, JA | 1 |
| Liu, H | 1 |
| Martenson, JA | 1 |
| Bearden, JD | 1 |
| Sapiente, R | 1 |
| Seeger, GR | 1 |
| Mowat, RB | 1 |
| Liem, B | 1 |
| Iott, MJ | 1 |
| Loprinzi, CL | 1 |
| Luchini, AC | 1 |
| Rodrigues-Orsi, P | 1 |
| Cestari, SH | 1 |
| Seito, LN | 1 |
| Witaicenis, A | 1 |
| Pellizzon, CH | 1 |
| Di Stasi, LC | 1 |
| van der Kooij, SM | 1 |
| Goekoop-Ruiterman, YP | 1 |
| de Vries-Bouwstra, JK | 1 |
| Güler-Yüksel, M | 1 |
| Zwinderman, AH | 1 |
| Kerstens, PJ | 1 |
| van der Lubbe, PA | 1 |
| de Beus, WM | 1 |
| Grillet, BA | 1 |
| Ronday, HK | 1 |
| Huizinga, TW | 1 |
| Breedveld, FC | 2 |
| Dijkmans, BA | 2 |
| Allaart, CF | 1 |
| Son, CN | 1 |
| Lee, HL | 1 |
| Joo, YW | 1 |
| Lee, OY | 1 |
| Han, DS | 1 |
| Yoon, BC | 1 |
| Choi, HS | 1 |
| Hahm, JS | 1 |
| Augusto, JF | 1 |
| Sayegh, J | 1 |
| Simon, A | 1 |
| Croue, A | 1 |
| Chennebault, JM | 1 |
| Cousin, M | 1 |
| Subra, JF | 1 |
| Pitchumoni, CS | 1 |
| Rubin, A | 1 |
| Das, K | 1 |
| Alivanis, P | 1 |
| Aperis, G | 1 |
| Lambrianou, F | 1 |
| Zervos, A | 1 |
| Paliouras, C | 1 |
| Karvouniaris, N | 1 |
| Arvanitis, A | 1 |
| Wakefield, D | 1 |
| Chang, JH | 1 |
| Amjadi, S | 1 |
| Maconochie, Z | 1 |
| Abu El-Asrar, A | 1 |
| McCluskey, P | 1 |
| He, J | 1 |
| Liang, J | 1 |
| Zhu, S | 1 |
| Li, J | 1 |
| Zhang, Y | 1 |
| Sun, W | 1 |
| Schroeder, KW | 1 |
| Aletaha, D | 1 |
| Smolen, JS | 1 |
| Nagy, F | 1 |
| Muñoz-Fernández, S | 1 |
| Hidalgo, V | 1 |
| Fernández-Melón, J | 1 |
| Schlincker, A | 1 |
| Bonilla, G | 1 |
| Ruiz-Sancho, D | 1 |
| Fonseca, A | 1 |
| Gijón-Baños, J | 1 |
| Martín-Mola, E | 1 |
| Fransen, J | 1 |
| Stucki, G | 1 |
| Twisk, J | 1 |
| Chamot, AM | 1 |
| Gerster, JC | 1 |
| Langenegger, T | 1 |
| Seitz, M | 1 |
| Michel, BA | 1 |
| Munk, EM | 1 |
| Pedersen, L | 1 |
| Floyd, A | 1 |
| Nørgård, B | 1 |
| Rasmussen, HH | 1 |
| Sørensen, HT | 1 |
| Hisada, T | 1 |
| Miyamae, Y | 1 |
| Mizuide, M | 1 |
| Shibusawa, N | 1 |
| Iida, T | 1 |
| Masuo, T | 1 |
| Okada, S | 1 |
| Sagawa, T | 1 |
| Ishizuka, T | 1 |
| Kusano, M | 1 |
| Mori, M | 1 |
| Bergman, R | 1 |
| Parkes, M | 1 |
| Cohen, HD | 1 |
| Das, KM | 1 |
| Eloy, P | 1 |
| Leruth, E | 1 |
| Goffart, Y | 1 |
| Nollevaux, MC | 1 |
| Fridman, V | 1 |
| Dartevelle, M | 1 |
| Melange, M | 1 |
| Daele, J | 1 |
| Bertrand, B | 1 |
| Zimmerer, T | 1 |
| Böcker, U | 1 |
| Wenz, F | 1 |
| Singer, MV | 1 |
| Singleton, JW | 1 |
| Jewell, DP | 1 |
| Bläker, F | 1 |
| Schäfer, KH | 1 |
| Campieri, M | 2 |
| Lanfranchi, GA | 1 |
| Brignola, C | 1 |
| Bazzocchi, G | 1 |
| Minguzzi, MR | 1 |
| Calari, MT | 1 |
| Hermanowicz, A | 1 |
| Nowak, A | 1 |
| Gajos, L | 1 |
| Ruppin, H | 1 |
| Domschke, S | 1 |
| Cobden, I | 1 |
| Malchow, H | 1 |
| Lankisch, PG | 1 |
| Dröge, M | 1 |
| Gottesleben, F | 1 |
| Garau, P | 1 |
| Orenstein, SR | 1 |
| Neigut, DA | 1 |
| Kocoshis, SA | 1 |
| Debongnie, JC | 1 |
| Dekoninck, X | 1 |
| Yamada, T | 1 |
| Deitch, E | 1 |
| Specian, RD | 1 |
| Perry, MA | 1 |
| Sartor, RB | 1 |
| Grisham, MB | 1 |
| Ferzoco, SJ | 1 |
| Becker, JM | 1 |
| Turunen, U | 1 |
| Järvinen, HJ | 1 |
| Yamagiwa, I | 1 |
| Obata, K | 1 |
| Hatanaka, Y | 1 |
| Saito, H | 1 |
| Washio, M | 1 |
| Marce, S | 1 |
| Schaeverbeke, T | 1 |
| Bannwarth, B | 1 |
| Marty, L | 1 |
| Dehais, J | 1 |
| Omata, F | 1 |
| Arakawa, S | 1 |
| Takahashi, H | 1 |
| Ueno, F | 1 |
| Schoonjans, R | 1 |
| Mast, A | 1 |
| Van Den Abeele, G | 1 |
| Dewilde, D | 1 |
| Achten, E | 1 |
| Van Maele, V | 1 |
| Pauwels, W | 1 |
| Schölmerich, J | 1 |
| ten Wolde, S | 1 |
| Hermans, J | 1 |
| Dunn, RJ | 1 |
| Jajić, Z | 1 |
| Jajić, I | 1 |
| Burmester, GR | 1 |
| Feist, E | 1 |
| Krause, A | 1 |
| Arenas Gracia, M | 1 |
| Mata Medina, B | 1 |
| Serrano Corredor, MS | 1 |
| Calduch Broseta, JV | 1 |
| Martínez López, V | 1 |
| Segarra Soria, MM | 1 |
| Gálvez, J | 1 |
| Garrido, M | 1 |
| Merlos, M | 1 |
| Torres, MI | 1 |
| Zarzuelo, A | 1 |
| Kiliç, D | 1 |
| Egehan, I | 1 |
| Ozenirler, S | 1 |
| Dursun, A | 1 |
| Van Gossum, A | 1 |
| Chadenat, ML | 1 |
| Morelon, S | 1 |
| Dupont, C | 1 |
| Dechy, H | 1 |
| Raffin-Sanson, ML | 1 |
| Dorra, M | 1 |
| Rouveix, E | 1 |
| Martin, L | 1 |
| Hazouard, E | 1 |
| Michalak-Provost, S | 1 |
| Maurage, C | 1 |
| Machet, L | 1 |
| Seo, M | 1 |
| Okada, M | 1 |
| Yao, T | 1 |
| Matake, H | 1 |
| Maeda, K | 1 |
| Ishikawa, M | 1 |
| Tsuboi, M | 1 |
| Binder, SC | 1 |
| Katz, B | 1 |
| Simpson, WT | 1 |
| Müller-Schoop, J | 1 |
| Buckell, NA | 1 |
| Lennard-Jones, JE | 1 |
| Caprilli, R | 1 |
| Carratù, R | 1 |
| Babbini, M | 1 |
| Goebell, H | 2 |
| Eigler, FW | 1 |
| Hamadeh, MA | 1 |
| Atkinson, J | 1 |
| Smith, LJ | 1 |
| Bodokh, I | 1 |
| Lacour, JP | 1 |
| Perrin, C | 1 |
| Gallais, V | 1 |
| Ortonne, JP | 1 |
| Labayle, D | 1 |
| Delas, N | 1 |
| Pariente, A | 1 |
| Drouhin, F | 1 |
| Naouri, D | 1 |
| Bernard, B | 1 |
| Fischer, D | 1 |
| Delgado Fontaneda, E | 1 |
| García Campos, F | 1 |
| Ruiz Rebollo, L | 1 |
| Ibarra Peña, B | 1 |
| Moretó Canela, M | 1 |
| Aubry, A | 1 |
| Alandry, C | 1 |
| Lemiere, C | 1 |
| Woodhouse, KW | 1 |
| Farr, M | 1 |
| Symmons, DP | 1 |
| Blake, DR | 1 |
| Bacon, PA | 1 |
| Cappello, M | 1 |
| Puleo, A | 1 |
| Calabrese, A | 1 |
| Cipolla, C | 1 |
| Orlando, A | 1 |
| Gatto, G | 1 |
| Oliva, L | 1 |
| Cottone, M | 1 |
| Chiba, M | 1 |
| Horie, Y | 1 |
| Ishida, H | 1 |
| Arakawa, H | 1 |
| Masamune, O | 1 |
| Gilat, T | 1 |
| Suissa, A | 1 |
| Leichtman, G | 1 |
| Delpre, G | 1 |
| Pavlotzky, M | 1 |
| Grossman, A | 1 |
| Fireman, Z | 1 |
| Laurikainen, J | 1 |
| Hannonen, P | 1 |
| Oka, M | 1 |
| Fleig, WE | 1 |
| Laudage, G | 1 |
| Sommer, H | 1 |
| Wellmann, W | 1 |
| Stange, EF | 1 |
| Riemann, J | 1 |
| Karnaukhov, VK | 1 |
| Gheorghiu, T | 1 |
| Frotz, H | 1 |
| Binder, V | 1 |
| Söltoft, J | 1 |
| Gudmand-Höyer, E | 1 |
| Sergevnin, VV | 1 |
| Iudin, IIu | 1 |
| Krasnova, AI | 1 |
| Zvanitaĭs, VI | 1 |
| Daniliuk, SS | 1 |
| Kümmerle, F | 1 |
| Schier, J | 1 |
| Gillies, M | 1 |
| Skyring, A | 1 |
| Kühn, HA | 1 |
| Schultis, K | 1 |
| Edmonds, CJ | 1 |
| Schmidt, H | 1 |
| Uhl, N | 1 |
| Hunstein, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy[NCT01198145] | Phase 3 | 87 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163] | 26 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available) | |||
| An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982] | Phase 2 | 0 participants (Actual) | Interventional | 2007-08-07 | Withdrawn | ||
| Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease[NCT00152620] | 40 participants | Interventional | 2004-06-30 | Terminated (stopped due to study completed) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of patients reporting the use of anti-diarrheal medications divided by the number of patients evaluated for this endpoint. (NCT01198145)
Timeframe: Up to 24 months post radiotherapy
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I: Sulfasalazine | 48.7 |
| Arm II: Placebo | 28.6 |
"Questions that were used in this analysis:~2. Have you had a problem causing you to get up at night to have a bowel movement? 3. Have you had a problem causing you to lose control of your bowel movements? 4. Have you had a problem causing you to have a bowel movement within 30 minutes of a prior bowel movement? 5. Have you had to wear protective clothing or a pad in case you lost control of a bowel movement? 6. Have you had a problem causing you to be unable to tell the difference between stool and gas? 7. Have you had a problem causing you to have stools that are liquid? 1=yes 2=no q08 8. Have you found that once you feel the urge to have a bowel movement, you must do so within 15 minutes to avoid an accident? 9. Have you had cramping with a bowel movement? 10. Have you had blood in your bowel movement?" (NCT01198145)
Timeframe: Up to 6 weeks post radiation therapy
| Intervention | percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| During RT : Q2 | During RT : Q3 | During RT : Q4 | During RT : Q5 | During RT : Q6 | During RT : Q7 | During RT : Q8 | During RT : Q9 | During RT : Q10 | After RT : Q2 | After RT : Q3 | After RT : Q4 | After RT : Q5 | After RT : Q6 | After RT : Q7 | After RT : Q8 | After RT : Q9 | After RT : Q10 | |
| Arm I: Sulfasalazine | 19 | 11 | 33 | 7 | 26 | 11 | 44 | 4 | 7 | 39 | 24 | 55 | 18 | 37 | 37 | 70 | 34 | 50 |
| Arm II: Placebo | 10 | 10 | 33 | 0 | 23 | 20 | 43 | 17 | 7 | 27 | 22 | 56 | 12 | 46 | 37 | 61 | 34 | 29 |
For each patient, an Area Under the Curve (AUC) summary statistic will be calculated taking into account the individual severity of diarrhea toxicity over time. Severity of diarrhea was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. The curve was constructed using weekly assessments during and after RT. A separate analysis was done during the course of RT and every week for 6 weeks following RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | grade*week (Mean) | |
|---|---|---|
| During RT | After RT | |
| Arm I: Sulfasalazine | 4.0 | 1.2 |
| Arm II: Placebo | 3.3 | 1.3 |
Tenesmus, Abdominal pain, constipation, diarrhea and hemorrhaging were assessed during RT and up to 6 weeks after RT. Severity of these events were graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. For each patient, an average score for each outcome variable during and after RT calculated as follows: The sum of all severity scores for that variable divided by the number of severity scores for that variable recorded for the patient during the course of RT and for 6 weeks following RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Average Grade of Event (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT | Tenesmus after RT | Abdominal pain during RT | Abdominal pain after RT | Constipation during RT | Constipation after RT | Diarrhea during RT | Diarrhea after RT | Rectal bleeding during RT | Rectal bleeding after RT | |
| Arm I: Sulfasalazine | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.1 | 0.8 | 0.3 | 0.2 | 0.1 |
| Arm II: Placebo | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.6 | 0.3 | 0.2 | 0.1 |
"The primary endpoint for this study is the maximal severity of diarrhea toxicity. Severity of diarrhea was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening as measured by the CTCAE version 4.0. Assessments were recorded during the course of RT and for 6 weeks following RT. The table below represents the worst graded diarrhea for each patient.~A two-sided Wilcoxon rank-sum test will be used to test the equality of the distributions of maximum diarrhea severity grades between the two treatment arms." (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Arm I: Sulfasalazine | 10 | 13 | 8 | 10 | 1 |
| Arm II: Placebo | 10 | 15 | 13 | 4 | 0 |
For each arm, the percentage of patients experience clinically significant deficits in overall QOL and fatigue as indicated by a score of 5 or lower on the 0-10 scale. The analysis was done using the questionnaire that was completed during the first week of radiotherapy (RT) and 6 weeks after RT. (NCT01198145)
Timeframe: Up to 6 weeks post radiotherapy
| Intervention | percentage of participants (Number) | |
|---|---|---|
| During RT | After RT | |
| Arm I: Sulfasalazine | 17.9 | 26.9 |
| Arm II: Placebo | 7.5 | 27.6 |
The number of patients that reported any grade 1 or higher adverse event was divided by the total number of patients evaluated. The analysis was done separately for each of the 5 outcomes and separately during RT and after RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT | Tenesmus after RT | Abdominal pain during RT | Abdominal pain after RT | Constipation during RT | Constipation after RT | Diarrhea during RT | Diarrhea after RT | Rectal bleeding during RT | Rectal bleeding after RT | |
| Arm I: Sulfasalazine | 35.7 | 11.9 | 47.6 | 19.1 | 38.1 | 14.3 | 76.2 | 33.3 | 38.1 | 11.9 |
| Arm II: Placebo | 28.6 | 19.1 | 38.1 | 11.9 | 35.7 | 16.7 | 73.8 | 35.7 | 47.6 | 4.8 |
"The maximal severity of each of 5 different adverse even types (Tenesmus, Abdominal Pain, Constipation, Diarrhea, and Rectal Bleeding) were collected as a secondary endpoint. Severity of the events was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. Adverse events were assessed during the course of RT and for 6 weeks following RT. The table below represents the worst grade for each patient for each type.~Two-sided chi-square tests will be used to compare each percentage variable between treatment arms for each event type." (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT72333267 | Tenesmus during RT72333269 | Tenesmus after RT72333267 | Tenesmus after RT72333269 | Abdominal pain during RT72333267 | Abdominal pain during RT72333269 | Abdominal pain after RT72333269 | Abdominal pain after RT72333267 | Constipation during RT72333267 | Constipation during RT72333269 | Constipation after RT72333269 | Constipation after RT72333267 | Diarrhea during RT72333267 | Diarrhea during RT72333269 | Diarrhea after RT72333269 | Diarrhea after RT72333267 | Rectal bleeding during RT72333267 | Rectal bleeding during RT72333269 | Rectal bleeding after RT72333267 | Rectal bleeding after RT72333269 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Grade 0 | Grade 1 | Grade 4 | Grade 2 | Grade 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks
| Intervention | score on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hpynotherapy | 7 |
| UC Patients Given Control Educational Sessions | 10 |
Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 1.5 |
| UC Patients Given Control Educational Sessions | 4 |
IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 195 |
| UC Patients Given Control Educational Sessions | 192 |
Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 0.3 |
| UC Patients Given Control Educational Sessions | 0.4 |
The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 8 |
| UC Patients Given Control Educational Sessions | 7 |
15 reviews available for sulfasalazine and Acute Disease
| Article | Year |
|---|---|
Drug-induced eosinophilic pneumonia: A review of 196 case reports.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic Diseas | 2018 |
Pancreatitis in inflammatory bowel diseases.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Dis | 2010 |
What is new HLA-B27 acute anterior uveitis?
Topics: Acute Disease; Administration, Topical; Adrenal Cortex Hormones; Animals; Arthritis; Bacterial Infec | 2011 |
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory | 2002 |
[Conservative therapy of inflammatory bowel diseases].
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro | 2002 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Medical prevention and treatment of acute and chronic radiation induced enteritis--is there any proven therapy? a short review.
Topics: Abdominal Neoplasms; Acute Disease; Chronic Disease; Combined Modality Therapy; Controlled Clinical | 2008 |
Management of acute colitis.
Topics: Acute Disease; Colitis; Diagnosis, Differential; Humans; Prednisolone; Radiography; Sigmoidoscopy; S | 1984 |
[The treatment of ulcerative colitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamin | 1993 |
[Treatment and recurrence prevention ulcerative colitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroida | 1995 |
[Lymphocytic colitis: hypopotassemia as a complication and an association with toxic multinodular goiter].
Topics: Acute Disease; Chronic Disease; Colitis; Diagnosis, Differential; Diarrhea; Female; Gastrointestinal | 2000 |
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.
Topics: Acute Disease; Aspirin; Beclomethasone; Budesonide; Colitis, Ulcerative; Crohn Disease; Drug Therapy | 2002 |
[Long-term therapy and timing of surgical intervention in ulcerative colitis and Crohn disease].
Topics: Acute Disease; Aminosalicylic Acids; Colitis, Ulcerative; Combined Modality Therapy; Crohn Disease; | 1992 |
Drugs and the ageing gut, liver and pancreas.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Animals; Antacids; Anti-Ulcer Agen | 1985 |
9 trials available for sulfasalazine and Acute Disease
| Article | Year |
|---|---|
N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Enteritis; Female; Hum | 2016 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2009 |
Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Huma | 2003 |
Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial.
Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hu | 2003 |
Controlled therapeutic trial of levamisole and sulphasalazine in acute ulcerative colitis.
Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Colitis, Ulcerative; Drug Therapy, Combination | 1984 |
Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy.
Topics: Acute Disease; Administration, Oral; Aged; Chi-Square Distribution; Diarrhea; Double-Blind Method; F | 2000 |
Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report.
Topics: Acute Disease; Adolescent; Adult; Aged; Azathioprine; Biopsy; Clinical Trials as Topic; Colitis; Dru | 1975 |
A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial.
Topics: Acute Disease; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Female; Humans; I | 1987 |
Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Clinical Trials | 1988 |
60 other studies available for sulfasalazine and Acute Disease
| Article | Year |
|---|---|
Synthesis and Structure-Activity Relationships of Quaternary Coptisine Derivatives as Potential Anti-ulcerative Colitis Agents.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Berberine; Cell Line; Colitis, Ulcerative; Colon; | 2015 |
Sulfasalazine induced acute pancreatitis in a patient with prior cholecystectomy.
Topics: Acute Disease; Cholecystectomy; Humans; Length of Stay; Pancreatitis; Sulfasalazine | 2021 |
The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis.
Topics: 4-Hydroxycoumarins; Acute Disease; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Chronic | 2008 |
[A case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Colitis, Ulce | 2008 |
A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis.
Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Eruption | 2009 |
Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids.
Topics: Acute Disease; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Male; Methylpr | 2010 |
Anti-inflammatory effects of Pulvis Fellis Suis extract in mice with ulcerative colitis.
Topics: Acute Disease; Animals; Bile; Biological Products; Colitis, Ulcerative; Colon; Cyclooxygenase 2 Inhi | 2011 |
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Topics: Acute Disease; Aged; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Chron | 2002 |
Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
Topics: Acute Disease; Adult; Age Distribution; Aged; Aminosalicylic Acids; Case-Control Studies; Confidence | 2004 |
Acute thrombocytopenia associated with preexisting ulcerative colitis successfully treated with colectomy.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Colectomy; Colitis, Ulcerative; Glucocorticoids; Hum | 2006 |
Sinonasal involvement as a rare extraintestinal manifestation of Crohn's disease.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Crohn Disease; Diagnosis, Differential; Eth | 2007 |
Medical therapy of inflammatory bowel disease.
Topics: Acute Disease; Adjuvants, Immunologic; Anus Diseases; Azathioprine; Colitis, Ulcerative; Crohn Disea | 1980 |
Diagnosis and medical treatment of ulcerative colitis.
Topics: Acute Disease; Adrenal Cortex Hormones; Colectomy; Colitis, Ulcerative; Diagnosis, Differential; Hum | 1982 |
Immunopathology of ulcerative colitis and Crohn's disease, nonsurgical therapeutic considerations.
Topics: Acute Disease; Antibody Formation; Child; Colitis, Ulcerative; Crohn Disease; Glucocorticoids; Human | 1982 |
5-aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine.
Topics: Acute Disease; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; | 1984 |
Acute ulcerative colitis--a rare complication of sulfasalazine therapy.
Topics: Acute Disease; Adult; Colitis, Ulcerative; Female; Humans; Metronidazole; Sulfasalazine | 1984 |
[Therapy of chronic inflammatory bowel diseases].
Topics: Acute Disease; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Mercaptopurine; Methylpredn | 1983 |
Drug induced acute pancreatitis: incidence and severity.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Azathioprine; Didanosine; Estrogens; Female; Furosemi | 1995 |
Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis.
Topics: Acute Disease; Adolescent; Aminosalicylic Acids; Amylases; Child; Colitis, Ulcerative; Female; Human | 1994 |
Sulfasalazine, 5-ASA and acute pancreatitis in crohn's disease.
Topics: Acute Disease; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; | 1994 |
Mechanisms of acute and chronic intestinal inflammation induced by indomethacin.
Topics: Acute Disease; Animals; Bacteria; Bile; Chronic Disease; Disease Models, Animal; Enteritis; Indometh | 1993 |
Does aggressive medical therapy for acute ulcerative colitis result in a higher incidence of staged colectomy?
Topics: Acute Disease; Adolescent; Adult; Colectomy; Colitis, Ulcerative; Crohn Disease; Female; Glucocortic | 1994 |
Ischemic colitis complicating severe acute pancreatitis in a child.
Topics: Acute Disease; Child, Preschool; Colitis, Ischemic; Colon; Colonoscopy; Female; Gabexate; Humans; Pa | 1993 |
[Generalized acute exanthematous pustulosis after ingestion of sulfasalazine].
Topics: Acute Disease; Dermatitis, Exfoliative; Drug Eruptions; Humans; Male; Middle Aged; Psoriasis; Sulfas | 1993 |
Crohn's disease associated with pancreatitis of unknown etiology: a case report.
Topics: Acute Disease; Adult; Crohn Disease; Humans; Male; Metronidazole; Pancreatitis; Parenteral Nutrition | 1993 |
Sulfasalazine-associated encephalopathy in a patient with Crohn's disease.
Topics: Acute Disease; Adult; Brain; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Crohn Dis | 1993 |
Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation.
Topics: Acute Disease; Aged; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Femal | 1997 |
Massive sulfasalazine and paracetamol ingestion causing acidosis, hyperglycemia, coagulopathy, and methemoglobinemia.
Topics: Acetaminophen; Acetylcysteine; Acidosis, Lactic; Acute Disease; Adult; Anti-Inflammatory Agents; Blo | 1998 |
[Acute psychoses in patients with psoriatic arthritis during treatment with sulfasalazine].
Topics: Acute Disease; Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Middle Aged; Psychoses, S | 1998 |
[Reactive arthritis. Diagnosis, differential diagnosis and therapy].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Reactive; Arthritis, R | 1999 |
Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.
Topics: Acute Disease; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Aza Compounds; Chronic Disea | 2000 |
[Therapy of chronic inflammatory intestinal disease].
Topics: Acute Disease; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Budesonide; Chronic D | 2000 |
[Sulfasalazine neurotoxicity].
Topics: Acute Disease; Adult; Antirheumatic Agents; Arthritis; Encephalitis; Epilepsy; Female; Humans; Sulfa | 2001 |
[Fatal toxic respiratory epitheliolysis. Subacute tracheo-bronchial desquamation in Stevens-Johnson syndrome].
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Autopsy; Bronchial Diseases; Bro | 2001 |
Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ster | 2002 |
[Ulcerative colitis and its management, with special reference to the acute attack and its management].
Topics: Acute Disease; Colitis, Ulcerative; Humans; Prednisolone; Sulfasalazine | 1977 |
Management of severe attacks of ulcerative colitis.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Colitis, Ulcerative; Humans; Sulfa | 1978 |
Adrenal hemorrhage during the treatment of ulcerative colitis with adrenocorticotropic hormone.
Topics: Acute Disease; Adrenal Gland Diseases; Adrenocorticotropic Hormone; Colitis, Ulcerative; Hemorrhage; | 1979 |
[Immunosuppressive drugs in intestinal diseases (author's transl)].
Topics: Acute Disease; Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Im | 1979 |
How district hospitals see acute colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Colectomy; Colitis, Ulcerative; Crohn Disease; Female | 1979 |
Sulfasalazine-induced pulmonary disease.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Crohn Disease; Female; Humans; Male; Pulmonary Fibrosis; | 1992 |
[Hazards of treatment of psoriasis with sulfasalozine].
Topics: Acute Disease; Exanthema; Humans; Male; Middle Aged; Psoriasis; Risk Factors; Sulfasalazine | 1992 |
[Severe psychiatric disorders associated with severe acute colitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antid | 1992 |
[Acute pancreatitis caused by salazopyrine. An unusual association].
Topics: Acute Disease; Adult; Drug Combinations; Glucosamine; Humans; Male; Pancreatitis; Sulfasalazine | 1991 |
[Acute pancreatitis during treatment with salazosulfapyridine].
Topics: Acute Disease; Adult; Colitis, Ulcerative; Humans; Male; Pancreatitis; Sulfasalazine | 1989 |
Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.
Topics: Acute Disease; Adult; Agranulocytosis; Arthritis; Humans; Leukopenia; Male; Middle Aged; Neutropenia | 1986 |
[5-aminosalicylic acid treatment of ulcerative colitis during the acute phase in patients resistant or intolerant to salazopyrine].
Topics: Acute Disease; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Combinations; Drug Erupt | 1987 |
A case of salicylazosulfapyridine (Salazopyrin)-induced acute pancreatitis with positive lymphocyte stimulation test (LST).
Topics: Acute Disease; Adult; Colitis, Ulcerative; Drug Hypersensitivity; Humans; In Vitro Techniques; Lymph | 1987 |
[Acute rheumatoid arthritis--unsolved problems in treatment].
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Humans; Male; Prednisolone; Sulfasalazine | 1988 |
[Acute manifestations in Crohn disease and ulcerative colitis. Conservative treatment of acute situations].
Topics: Acute Disease; Aminosalicylic Acids; Colitis, Ulcerative; Combined Modality Therapy; Crohn Disease; | 1988 |
[Experience in the treatment of nonspecific ulcerative colitis].
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Child; Child | 1973 |
[Ulcerative colitis].
Topics: Acute Disease; Adult; Aged; Chronic Disease; Colitis, Ulcerative; Colonic Neoplasms; Diagnosis, Diff | 1973 |
Histological and histochemical changes in the jejunal mucosa in ulcerative colitis.
Topics: Acid Phosphatase; Acute Disease; Alkaline Phosphatase; Biopsy; Chronic Disease; Colectomy; Colitis, | 1974 |
[Use of salazopyridazine in sphincter-preserving operations for nonspecific ulcerative colitis].
Topics: Acute Disease; Adult; Chronic Disease; Colectomy; Colitis, Ulcerative; Drug Combinations; Humans; Mi | 1974 |
[Regional enteritis].
Topics: Acute Disease; Adult; Age Factors; Chronic Disease; Crohn Disease; Diagnosis, Differential; Diet The | 1968 |
Ulcerative colitis: the experience of a Sydney teaching hospital.
Topics: Acute Disease; Adolescent; Adult; Australia; Bile Duct Neoplasms; Carcinoma; Child; Child, Preschool | 1970 |
[Therapy of ulcerative colitis].
Topics: Acute Disease; Chronic Disease; Colectomy; Colitis, Ulcerative; Diet Therapy; Glucocorticoids; Human | 1970 |
Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and ulcerative colitis.
Topics: Acute Disease; Biological Transport, Active; Colitis, Ulcerative; Colon, Sigmoid; Colonic Diseases, | 1970 |
[Isolated aplastic anemia (acute benign erythroblastopenia of Gasser) in ulcerative colitis].
Topics: Acute Disease; Adult; Anemia, Aplastic; Anemia, Macrocytic; Anti-Bacterial Agents; Colitis, Ulcerati | 1970 |